ArticleFrontiers in immunology2022
Gut Mycobiome in Patients With Chronic Kidney Disease Was Altered and Associated With Immunological Profiles.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- Mind the Gut: Cognitive Decline, Microbiota, and Nutrition-Related Modulators in Older Adults with Chronic Kidney Disease.Nutrients · 2026Review
- Microbiota-driven mechanisms in multisystem diseases: integrative evidence across cardiovascular, metabolic, neurological and autoimmune disorders.Antonie van Leeuwenhoek · 2026Review
- Microbiota-derived metabolites and cognitive dysfunction in dialysis patients: mechanisms and targeted therapeutic strategies.Frontiers in microbiology · 2026Review
- The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025Review
- Dietary Intake and Gut Microbiome in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025Review
- The mechanism of enterogenous toxin methylmalonic acid aggravating calcium-phosphorus metabolic disorder in uremic rats by regulating the Wnt/β-catenin pathway.Molecular medicine (Cambridge, Mass.) · 2025Article
- The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.Theranostics · 2025Review
- From Skin and Gut to the Brain: The Infectious Journey of the Human Commensal Fungus Malassezia and Its Neurological Consequences.Molecular neurobiology · 2025Review
- Article
- The compositional and functional imbalance of the gut microbiota in CKD linked to disease patterns.Journal of translational medicine · 2024Article
- Altered gut mycobiome in patients with end-stage renal disease and its correlations with serum and fecal metabolomes.Journal of translational medicine · 2024Article
- Causal relationship between gut microbiota and chronic renal failure: a two-sample Mendelian randomization study.Frontiers in microbiology · 2024Article
- Washed microbiota transplantation improves renal function in patients with renal dysfunction: a retrospective cohort study.Journal of translational medicine · 2023Article
- Alteration in gut mycobiota of patients with polycystic ovary syndrome.Microbiology spectrum · 2023Article
- Chronic kidney disease and gut microbiota.Heliyon · 2023Review
- Exploring the gut mycobiome: differential composition and clinical associations in hypertension, chronic kidney disease, and their comorbidity.Frontiers in immunology · 2023Article
- Fungal gut microbiota dysbiosis in systemic lupus erythematosus.Frontiers in microbiology · 2023Article
- The Human Mycobiome: Colonization, Composition and the Role in Health and Disease.Journal of fungi (Basel, Switzerland) · 2022Review
- Gut mycobiome dysbiosis contributes to the development of hypertension and its response to immunoglobulin light chains.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Mounting evidence suggests that bacterial dysbiosis and immunity disorder are associated with patients with chronic kidney disease (CKD), but the mycobiome is beginning to gain recognition as a fundamental part of our microbiome. We aim to characterize the profile of the mycobiome in the gut of CKD patients and its correlation to serum immunological profiles. Methods and materials: Ninety-two CKD patients and sex-age-body mass index (BMI)-matched healthy controls (HCs) were recruited. Fresh samples were collected using sterile containers. ITS transcribed spacer ribosomal RNA gene sequencing was performed on the samples. An immunoturbidimetric test was used to assess the serum levels of immunological features. Results: The CKD cohort displayed a different microbial community from that in the HC cohort according to principal coordinate analysis (PCoA). ( Conclusions: Not only was gut mycobiome dysbiosis observed in CKD patients, but the dysbiosis was also associated with the immunological disorder. These findings suggest that therapeutic strategies targeting gut mycobiome might be effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.